NCT04553107

Reducing Costs by Deprescribing Medications

Completed NA Last updated 22 November 2022

What this trial tests

NA trial testing Deprescribing Intervention in Polypharmacy in 419 participants. Completed in 1 June 2022.

Timeline

9 December 2019

Primary endpoint
1 June 2022

1 June 2022

Quick facts

Lead sponsor	The University of Texas Health Science Center, Houston
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	other
Enrollment	419
Start date	9 December 2019
Primary completion	1 June 2022
Estimated completion	1 June 2022
Sites	1 location across United States

Drugs / interventions tested

• Deprescribing Intervention
• Usual Care

Conditions studied

• Polypharmacy — all drugs for Polypharmacy →
• Deprescribing — all drugs for Deprescribing →
• Adverse Drug Reaction — all drugs for Adverse Drug Reaction →

Sponsor

The University of Texas Health Science Center, Houston

Who can join

65 and older, any sex, with Polypharmacy or Deprescribing. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of the study is to implement a pharmacist-led deprescribing intervention for adults 65 and older taking 10 or more medications at University of Texas (UT) Physicians clinics and to assess the effect of the pharmacist intervention on the incidence of adverse drug reactions, emergency room visits, and hospitalizations as well as costs to the patient and to the healthcare system in adults 65 and older taking 10 or more medications treated at UT Physicians.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

1. Medication review in hospitalised patients to reduce morbidity and mortality.
   Bülow C, Clausen SS, Lundh A, Christensen M. · · 2023 · cited 37× · PMID 36688482 · DOI 10.1002/14651858.cd008986.pub4